Talazoparib is a potent poly‐ADP‐ribosyl polymerase (PARP) inhibitor that can induce synthetic lethality in cancers with deleterious germline mutations in BRCA. 119, 120A very recent study reported that talazoparib could dramatically upregulate expression of PLK4 to show the tumour inhibitory effect in HepG2 tumour cells, which provides us with a novel pathway to target PLK4/YAP axis for the treatment of HCC.118. This evidence concerns the gene YAP1 and hepatocellular carcinoma.